A Multinational, Multicenter, Randomized, Double-Blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer’s Disease
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Oral administration of cholinesterase inhibitors is often associated with adverse gastrointestinal effects, and so developing an alternative administration route, such as transdermal, is urgently needed. The primary objective of this study was to determine the efficacy and safety of the IPI-301 donepezil transdermal patch compared with donepezil tablets (control) in mild-to-moderate probable Alzheimer’s disease (AD). Methods This prospective, randomized, double-blind, double-dummy, two-arm parallel, multicenter trial included 399 patients, among whom 303 completed the trial. For randomization, the patients were stratified based on previous treatment and donepezil dose; patients in each stratum were randomized to the test and control groups at a 1:1 ratio. Results The difference between the control group and the IPI-301 group, quantified as the Hodges–Lehmann estimate of location shift, was 0.00 (95% confidence interval: -1.00 to 1.33), with an upper limit of less than 2.02. The change in Alzheimer’s Disease Cooperative Study– Activities of Daily Living (ADCS-ADL) score differed significantly between the IPI-301 and control groups (p=0.02). However, the changes in the full-itemized ADCS-ADL scores at week 24 did not differ significantly between the two groups. There were no differences between the two groups regarding the scores for the Clinician Interview-Based Impression of Change (p=0.9097), Mini-Mental State Examination (p=0.7018), Neuropsychiatric Inventory (p=0.7656), or Clinical Dementia Rating (p=0.9990). Adverse events, vital signs, and laboratory test results were comparable between the two groups. Conclusions IPI-301 was safe and efficacious in improving cognitive function in patients with mild-to-moderate AD.
Abstract
Background and Purpose Oral administration of cholinesterase inhibitors is often associated with adverse gastrointestinal effects, and so developing an alternative administration route, such as transdermal, is urgently needed. The primary objective of this study was to determine the efficacy and safety of the IPI-301 donepezil transdermal patch compared with donepezil tablets (control) in mild-to-moderate probable Alzheimer’s disease (AD). Methods This prospective, randomized, double-blind, double-dummy, two-arm parallel, multicenter trial included 399 patients, among whom 303 completed the trial. For randomization, the patients were stratified based on previous treatment and donepezil dose; patients in each stratum were randomized to the test and control groups at a 1:1 ratio. Results The difference between the control group and the IPI-301 group, quantified as the Hodges–Lehmann estimate of location shift, was 0.00 (95% confidence interval: -1.00 to 1.33), with an upper limit of less than 2.02. The change in Alzheimer’s Disease Cooperative Study– Activities of Daily Living (ADCS-ADL) score differed significantly between the IPI-301 and control groups (p=0.02). However, the changes in the full-itemized ADCS-ADL scores at week 24 did not differ significantly between the two groups. There were no differences between the two groups regarding the scores for the Clinician Interview-Based Impression of Change (p=0.9097), Mini-Mental State Examination (p=0.7018), Neuropsychiatric Inventory (p=0.7656), or Clinical Dementia Rating (p=0.9990). Adverse events, vital signs, and laboratory test results were comparable between the two groups. Conclusions IPI-301 was safe and efficacious in improving cognitive function in patients with mild-to-moderate AD.
참고문헌 (30)
- Small GW, "Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society", JAMA, 278, pp.1363~1371 (1997)
- World Alzheimer Report 2018. The State of the Art of Dementia Research: New Frontiers, "Patterson C", Alzheimer’s Disease International, ~ (2018)
- Rogers SL, "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group", Neurology, 50, pp.136~145 (1998)
- Seltzer B, "Efficacy of donepezil in early-stage Alzheimer disease : a randomized placebo-controlled trial", Arch Neurol, 61, pp.1852~1856 (2004)
- Inglis F, "The tolerability and safety of cholinesterase inhibitors in the treatment of dementia", Int J Clin Pract Suppl, 127, pp.45~63 (2002)
- Cummings JL, "High-dose donepezil(23 mg", day)for the treatment of moderate and severe Alzheimer’s disease : drug profile and clinical guidelines, 2013, pp.19, 294~301
- Lee C, "Adverse events with sustained-release donepezil in Alzheimer disease : relation to body mass index", J Clin Psychopharmacol, 37, pp.401~404 (2017)
- Mauskopf JA, "Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings", J Manag Care Pharm, 11, pp.231~251 (2005)
- Utsuki T, "Preclinical investigation of the topical administration of phenserine : transdermal flux, cholinesterase inhibition, and cognitive efficacy", J Pharmacol Exp Ther, 321, pp.353~361 (2007)
- Winblad B, "Use of rivastigmine transdermal patch in the treatment of Alzheimer’s disease", Expert Opin Drug Deliv, 5, pp.1377~1386 (2008)
- Priano L, "Transdermal treatment options for neurological disorders : impact on the elderly", Drugs Aging, 23, pp.357~375 (2006)
- Bhowmik D, "Recent advances in transdermal drug delivery system", Int J Pharm Tech Res, 2, pp.68~77 (2010)
- Oertel W, "Rationale for transdermal drug administration in Alzheimer disease", Neurology, 69(4 Suppl 1), pp.S4~S9 (2007)
- Mohs RC, "Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study", Alzheimer Dis Assoc Disord, 11(Suppl 2), pp.S13~S21 (1997)
- Reisberg B, "Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines", Alzheimer Dis Assoc Disord, 11(Suppl 3), pp.8~18 (1997)
- Galasko D, "An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study", Alzheimer Dis Assoc Disord, 11, pp.S33~S39 (1997)
- Cummings JL, "The neuropsychiatric inventory : comprehensive assessment of psychopathology in dementia", Neurology, 44, pp.2308~2314 (1994)
- Posner K, "The Columbia-Suicide Severity Rating Scale : initial validity and internal consistency findings from three multisite studies with adolescents and adults", Am J Psychiatry, 168, pp.1266~1277 (2011)
- Cooper J, "Diagnostic and statistical manual of mental disorders(4th edn, text revision)(DSM–IV–TR)Washington, DC : American Psychiatric Association 2000", Br J Psychiatry, 179, pp.85~ (2001)
- McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
- Folstein MF, ""Mini-mental state". A practical method for grading the cognitive state of patients for the clinician", J Psychiatr Res, 12, pp.189~198 (1975)
- Morris JC, "The Clinical Dementia Rating(CDR) : current version and scoring rules", Neurology, 43, pp.2412~2414 (1993)
- Román GC, "Vascular dementia : diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop", Neurology, 43, pp.250~260 (1993)
- Dooley M, "Donepezil : a review of its use in Alzheimer’s disease", Drugs Aging, 16, pp.199~226 (2000)
- Hong YJ, "Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg : a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial", Alzheimers Res Ther, 11, pp.37~ (2019)
- Dunn NR, "Adverse effects associated with the use of donepezil in general practice in England", J Psychopharmacol, 14, pp.406~440 (2000)
- 한현정, "Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer’s Disease", Journal of Clinical Neurology, 7(3), pp.137~142 (2011), 대한신경과학회
- Kim YH, "Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers", Drug Des Devel Ther, 9, pp.1419~1426 (2015)
- Yoon SK, "Pharmacokinetic evaluation by modeling and simulation analysis of a donepezil patch formulation in healthy male volunteers", Drug Des Devel Ther, 14, pp.1729~1737 (2020)
- Sozio P, "Transdermal donepezil on the treatment of Alzheimer’s disease", Neuropsychiatr Dis Treat, 8, pp.361~368 (2012)